Universal Biocells Pte., Ltd.
Universal Biocells (China) Ltd is a wholly-owned subsidiary of Singapore - Universal Biocells Pte., Ltd, invested by British Cayman Islands - Universal Biocells Holding Inc. with a registered capital of 10 million yuan, and settled in Xiangjiang New Area in December 2025. The company mainly engages in cross-border sales of daily necessities, cosmetics, health food, etc., providing comprehensive cross-border e-commerce solutions such as global logistics, warehousing, and payment, covering B2B and B2C models, and deeply cultivating markets in Europe, America, Southeast Asia, and other regions. We plan to build a production base by the end of 2026, focusing on areas such as gene editing and industrialization of cell culture. Adhering to the concept of "excellent quality, favorable price", we aim to link global biotechnology resources and achieve two-way circulation of high-quality goods from China and abroad.
